Thank you for visiting FormulaScan . Please click on the Patent No to study the full patent document

WORLD PATENTS IN PHARMACEUTICAL EXCIPIENTS AND FORMULATIONS PUBLISHED IN 2010


Title: CROSS-LINKED POLYALLYLAMINE TABLET CORE

Publication No: WO2010/151439
Pub. Date - Int. Class - Applicant: - 29.12.2010 - A61K 31/74 - NAVINTA LLC
A method and a composition for making a composition, tablet, or tablet core having cross-linked polyallylamine salts such as sevelamer hydrochloride, sevelamer carbonate, or colesevelam hydrochloride, that may be used for treating hyperphosphatemia or reducing cholesterol. The method involves blending of a cross-linked polyallylamine salt with a water soluble excipient, optionally with water, an additive and /or a lubricant, and further tableting the resulting blend to form tablets and tablet cores.


Title: NOVEL PHARMACEUTICAL COMPOSITION COMPRISING POLY (ALLYLAMIN-CO-N,N'-DIALLYL- 1,3-DIAMINO-2-HYDROXYPROPANE)

Publication No: WO2010/149794
Pub. Date - Int. Class - Applicant: - 29.12.2010 - A61K 9/20 - COMBINO PHARM, S.L.
A solid, pharmaceutical composition for oral administration comprising from about 80% to about 94% by weight of sevelamer including the water of hydration and at least one pharmaceutically acceptable excipient.


Title: CLEC-2 IS AN ESSENTIAL PLATELET ACTIVATING RECEPTOR IN HEMOSTASIS AND THROMBOSIS

Publication No: WO2010/149664
Pub. Date - Int. Class - Applicant: - 29.12.2010 - A61P 7/02 - CSL Behring GmbH
The present invention relates to a pharmaceutical composition comprising an inhibitor of C-type lectin-like receptor 2 (CLEC-2) or an inhibitor of an activator of CLEC-2, each of which induces an irreversible inactivation or degradation of CLEC-2 on platelets, and optionally a pharmaceutically acceptable carrier, excipient and/or diluent. Furthermore, the present invention relates to an inhibitor of C-type lectin-like receptor 2 (CLEC-2) or an inhibitor of an activator of CLEC-2, each of which induces an irreversible inactivation or degradation of CLEC-2 on platelets, for use in treating or preventing a disorder related to venous or arterial thrombus formation and to the use of such an inhibitor as a lead compound for developing a drug for ...


Title: NOVEL PHARMACEUTICAL COMPOSITION COMPRISING POLY (ALLYLAMIN-CO-N,N'-DIALLYL- 1,3-DIAMINO-2-HYDROXYPROPANE) HYDROCHLORIDE

Publication No: WO2010/149230
Pub. Date - Int. Class - Applicant: - 29.12.2010 - A61K 9/20 - COMBINO PHARM, S.L.
Novel pharmaceutical composition comprising poly (allylamin-co-n,n'-diallyl- 1,3- diamino-2-hydroxypropane) hydrochloride. The invention solves the problem related to the high hygroscopicity of active principle sevelamer hydrochloride, which becomes even more serious if the formulation contains it at high concentrations, particularly if said formulation is a tablet. For solving this problem the formulations of the invention comprise an excipient pharmaceutically acceptable which acts as diluent, preferably a pregelatinized starch.


Title: TASTE MASKED DOSAGE FORM OF PHARMACEUTICALLY ACCEPTABLE SALT OF ESCITALOPRAM

Publication No: WO2010/149196
Pub. Date - Int. Class - Applicant: - 29.12.2010 - A61K 9/00 - GENEPHARM A.E.
A taste masked dosage form of pharmaceutical acceptable salt of escitalopram comprising (a) resin complex of pharmaceutical acceptable salt of escitalopram and cationic exchange resin or adsorbing or coating non-pareil seeds or inert particles with a mixture of pharmaceutically acceptable salt of escitalopram, cationic polymer and optionally other polymer(s) or loading non-pareil seeds or inert particles with pharmaceutically salt of escitalopram followed by polymer coating with cationic polymer and optionally other polymer(s); and (b) atleast one pharmaceutical excipient.


Title: INHIBITORS OF INFLUENZA VIRUSES REPLICATION

Publication No: WO2010/148197
Pub. Date - Int. Class - Applicant: - 23.12.2010 - A61K 31/506 - VERTEX PHARMACEUTICALS INCORPORATED
Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A compound is represented by Structural Formula (IA) or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A pharmaceutical composition comprises an effective amount of such a compound or pharmaceutically acceptable salt ...


Title: SOLID PHARMACEUTICAL COMPOSITION COMPRISING RIVAROXABAN

Publication No: WO2010/146179
Pub. Date - Int. Class - Applicant: - 23.12.2010 - A61K 9/20 - KRKA, TOVARNA ZDRAVIL, D.D., NOVO MESTO
The invention relates to a solid pharmaceutical composition comprising rivaroxaban, or a pharmaceutically acceptable salt or solvate thereof, and at least one pharmaceutically acceptable excipient. The invention also relates to a process for the preparation of a solid pharmaceutical composition comprising rivaroxaban, or a pharmaceutically acceptable salt or solvate thereof, the process comprising (a) providing a mixture comprising rivaroxaban and at least one pharmaceutically acceptable excipient and (b) converting said mixture to a solid pharmaceutical composition.


Title: DISSOLVABLE PHARMACEUTICAL IMPLANT

Publication No: WO2010/144849
Pub. Date - Int. Class - Applicant: - 16.12.2010 - A61K 9/00 - MEDTRONIC, INC.
A pharmaceutical implant may include a pharmaceutical and at least one excipient, and may be configured to be implanted in a body of a patient. The at least one excipient may dissolve after implantation of the pharmaceutical implant in the body of the patient and release the pharmaceutical. In some examples, the pharmaceutical implant includes at least two pharmaceuticals. The at least one excipient may be selected to provide a desired release profile of the pharmaceutical. For example, the pharmaceutical implant may be configured to dissolve and release the pharmaceutical over a length of time between about one day and about 30 days. In some examples, the pharmaceutical implant may be implanted in the body of the patient proximate to an im...


Title: NOVEL PHARMACEUTICAL COMPOSITIONS OF RANOLAZINE

Publication No: WO2010/137040
Pub. Date - Int. Class - Applicant: - 02.12.2010 - None - LUPIN LIMITED
A novel controlled release pharmaceutical dosage form comprising a therapeutically effective amount of ranolazine or pharmaceutically acceptable salt(s), polymorph(s), solvate(s), hydrate(s), enantiomer(s) thereof, one or more lipid(s) as release controlling agent(s) and one or more pharmaceutically acceptable excipient(s).


Title: STIM2-MEDIATED CAPACITIVE CALCIUM ENTRY

Publication No: WO2010/136577
Pub. Date - Int. Class - Applicant: - 02.12.2010 - A61K 39/395 - CSL BEHRING GMBH
The present invention relates to a pharmaceutical composition comprising an inhibitor of STIM2 or an inhibitor of STIM2-regulated plasma membrane calcium channel activity and optionally a pharmaceutically acceptable carrier, excipient and/or diluent. Furthermore, the present invention relates to an inhibitor of STIM2 or an inhibitor of STIM2-regulated plasma membrane calcium channel activity for the treatment and/or prevention of a neurological disorder associated with pathologically increased cytosolic calcium concentrations. The present invention also relates to a method of treating and/or preventing a neurological disorder associated with pathologically increased cytosolic calcium concentrations comprising administering a pharmaceuticall...


Title: PARMACEUTICAL COMPOSITION FOR THE TREATMENT OF HEART DISEASES.

Publication No: WO2010/133686
Pub. Date - Int. Class - Applicant: - 25.11.2010 - A61K 35/34 - CARDIO3 BIOSCIENCES S.A.
The present invention is related to a pharmaceutical composition comprising cells committed to the generation of heart tissue and at least one pharmaceutically acceptable excipient produced according to internationally recognized standards for pharmaceutical product manufacture, a process for the manufacture of such a pharmaceutical composition and a kit for the administration of said pharmaceutical composition which comprises a container containing said pharmaceutical composition.


Title: NOVEL PHARMACEUTICAL COMPOSITIONS OF CHOLINE FENOFIBRATE

Publication No: WO2010/131265
Pub. Date - Int. Class - Applicant: - 18.11.2010 - A61K 9/28 - LUPIN LIMITED
A controlled release pharmaceutical composition(s) comprising choline fenofibrate wherein the core comprises choline fenofibrate and auxiliary excipient and a coating layer comprising rate controlling agent(s). A controlled release pharmaceutical composition(s) comprising choline fenofibrate comprising an immediate release core wherein said core comprises choline fenofibrate, water soluble inert material with one or more auxiliary pharmaceutical excipient and a coating layer comprising rate controlling hydrophobic agent(s). A controlled release pharmaceutical composition(s) comprising choline fenofibrate comprising an immediate release core wherein said core comprises choline fenofibrate, water soluble inert material with one or more auxili...


Title: COMPOSITION

Publication No: WO2010/130982
Pub. Date - Int. Class - Applicant: - 18.11.2010 - A61K 9/16 - INNOVATA LIMITED
The invention provides microparticles comprising an immunosuppressant, such as tacrolimus, sirolimus, pimecrolimus, ciclosporin, everolimus or a derivative thereof, and optionally a pharmaceutically acceptable excipient or carrier, such as a saccharide, amino acid, a sugar alcohol or a mixture thereof, and having a median geometric diameter of less than, or equal to, about 10 µm and which have a tap density of less than or equal to about 0.3 g/cm3.


Title: TABLET PRODUCTION MODULE AND METHOD FOR CONTINUOUS PRODUCTION OF TABLETS

Publication No: WO2010/128359
Pub. Date - Int. Class - Applicant: - 11.11.2010 - A61J 3/10 - GEA Pharma Systems Limited
The contained module (1) comprises inlets for an active pharmaceutical ingredient (API) and for an excipient. The inlets are in fluid communication with at least one mixing unit (41,46), and the outlet of 5 the tablet press (6) is in fluid communication with the releasable outlet port for tablets. The material stream comprising the API and the excipient is mixed in the mixing units. During operation parameters of the contents of the material stream are measured with one or more analytical sensors upstream of the tablet press. The speed of the tablet press is 10 controlled in response to the parameters measured upstream of the tab- let press. The finished tablets are discharged at an outlet of the tablet press (6).


Title: COMPOSITIONS CONTAINING A MIXTURE OF LUTEIN AND ZEAXANTHINE AND COATED WITH CHOCOLATE

Publication No: WO2010/125516
Pub. Date - Int. Class - Applicant: - 04.11.2010 - A61K 9/00 - GRAAL SRL
The present invention refers to pharmaceutical, dietary and/or nutraceutical compositions containing a mixture of lutein and zeaxanthin alongside at least one physiologically acceptable excipient. In particular the invention refers to orobuccal, sublingual and/or effervescent compositions formulated in form of tablet, capsule, granules or pill. The present invention also refers to the abovementioned compositions for use in the treatment, human or veterinarian, of diseases or disorders of the eye.


Title: HUMAN SERUM ALBUMIN-BASED TOPICAL OINTMENT FOR TREATMENT OF ACNE, PSORIASIS, EGFR-INDUCED TOXICITY, PREMATURE SKIN AGING AND OTHER SKIN CONDITIONS

Publication No: WO2010/124280
Pub. Date - Int. Class - Applicant: - 28.10.2010 - A61K 38/38 - NEW CENTURY PHARMACEUTICALS, INC.
Dermatological compositions and method for treating psoriasis, eczema, acne and like skin conditions for sanitization, pharmaceutical compounding and protection of the skin from extreme environmental conditions are provided which contain serum albumin in an amount effective to treat, reduce the symptoms and improve the appearance of affected skin due to psoriasis, eczema, and acne and like conditions, enhance the delivery performance or stability of pharmaceutical compounding bases, protect the skin from the environment and premature aging, and to lubricate and/or promote the healing of eye after surgical or accidental trauma, when combined with a suitable topical ointment, antibacterial or dermatological agent, pharmaceutical compounding o...


Title: METHODS OF TREATMENT FOR SOLID TUMORS

Publication No: WO2010/123931
Pub. Date - Int. Class - Applicant: - 28.10.2010 - A61K 31/519 - CALISTOGA PHARMACEUTICALS INC.
The invention provides methods that relate to a novel therapeutic strategy for the treatment of hematological malignancies and inflammatory diseases. In particular, the method comprises administration of a compound of formula I, (I) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising such compound admixed with at least one pharmaceutically acceptable excipient.


Title: COMPOSITIONS AND METHODS FOR TREATING BURNS

Publication No: WO2010/123759
Pub. Date - Int. Class - Applicant: - 28.10.2010 - A61K 33/16 - HICKS, Terry, Lee
The present invention provides compositions and methods for treating burns comprising administering to a burn area of a subject in need thereof of a therapeutically effective amount of a composition comprising an anti-cytokine or anti-inflammatory agent or a functional derivative thereof; and a pharmaceutically acceptable excipient.


Title: PHARMACEUTICAL COMPOSITION COMPRISING 4-AMINO-8-(2-FLUORO-6-METHOXY-PHENYL)-N- PROPYLCINNOLINE-3-CARBOXAMIDE HYDROGEN SULPHATE.

Publication No: WO2010/123443
Pub. Date - Int. Class - Applicant: - 28.10.2010 - A61K 9/20 - ASTRAZENECA AB
Disclosed is a pharmaceutical composition for a cinnoline derivative in the gastrointestinal environment. The composition comprising a solid cinnoline derivative and at least one pharmaceutical excipient selected from a filler, a binder, a disintegrant, a suspending agent, a coating agent, a sweetener, a flavoring, and a lubricant.


Title: ORAL SUSPENSION OF DEXAMETHASONE ACETATE -TASTE MASKING COMPOSITION OF DEXAMETHASONE

Publication No: WO2010/119300
Pub. Date - Int. Class - Applicant: - 21.10.2010 - A61K 9/10 - CASSO PHARMACEUTICALS LTD.
The present invention is a pharmaceutically acceptable composition in the form of suspension for the oral delivery of dexamethasone acetate in which the active ingredient is homogenously dispersed in a pharmaceutically acceptable aqueous carrier -vehicle. The present invention relates to a method for taste masking the bad taste of dexamethasone, provide a pharmaceutical composition comprising a specific ester of dexamethasone (dexamethasone acetate), in a therapeutically effective amount in a aqueous, compatible, stable media vehicle and a suspending agent The inventive formulation comprising dexamethasone acetate dispersed in an aqueous, compatible, between about 0.4 mg/ml to about 40 mg/ml, more preferably between 0.4 mg/ml to about 10mg/...


Title: INHIBITORS OF FATTY ACID AMIDE HYDROLASE

Publication No: WO2010/118159
Pub. Date - Int. Class - Applicant: - 14.10.2010 - C07D 277/00 - INFINITY PHARMACEUTICALS, INC.
Provided herein are compounds of formula (I): or pharmaceutically acceptable salts, solvates or prodrugs thereof or mixtures thereof, wherein Z1, Z2, X1, X2, X3, R1, R2 R3, R4, m and n are defined herein. Also provided are pharmaceutically acceptable compositions that include a compound of formula I and a pharmaceutically acceptable excipient. Also provided are methods for treating an FAAH-mediated disorder comprising administering to a subject in need thereof a therapeutically effective amount of a compound or composition of the present invention.


Title: INHIBITORS OF FATTY ACID AMIDE HYDROLASE

Publication No: WO2010/118155
Pub. Date - Int. Class - Applicant: - 14.10.2010 - A01N 55/08 - INFINITY PHARMACEUTICALS, INC.
Provided herein are compounds of formula (I) or pharmaceutically acceptable salts, solvates or prodrugs thereof, or mixtures thereof, wherein Z1, Z2, X1, X2, X3, R1, R2 R3, m and n are defined herein. Also provided are pharmaceutically acceptable compositions that include a compound of formula I and a pharmaceutically acceptable excipient. Also provided are methods for treating FAAH-mediated disorders comprising administering to a subject in need thereof a therapeutically effective amount of a compound or composition of the present invention.


Title: PHARMACEUTICAL COMPOSITIONS FOR ALLEVIATING UNPLEASANT TASTE

Publication No: WO2010/116385
Pub. Date - Int. Class - Applicant: - 14.10.2010 - A61K 9/00 - RUBICON RESEARCH PRIVATE LIMITED
The present invention relates to oral pharmaceutical compositions that alleviate the bitter, unpleasant or metallic taste associated with eszopiclone therapy. The invention relates to pharmaceutical compositions comprising eszopiclone, at least one taste-masking agent and at least one pharmaceutically acceptable excipient. This taste-masked eszopiclone formulation that masks the immediate unpleasant or objectionable taste of eszopiclone is provided in dosage forms suitable for oral administration such as orally disintegrating tablets, bite-dispersion tablets, dispersible tablets, or the like. The invention further relates to a method of countering this unpleasant after-taste of eszopiclone comprising administering to the patients in need th...


Title: CURCUMINOIDS AND ITS METABOLITES FOR THE APPLICATION IN ALLERGIC OCULAR/NASAL CONDITIONS

Publication No: WO2010/109482
Pub. Date - Int. Class - Applicant: - 30.09.2010 - A01N 35/00 - LAILA PHARMACEUTICALS PVT. LTD.
A pharmaceutical composition(s) for ophthalmic/nasal administration comprising; one or more nano emulsified Curcumin component(s) and/or its metabolites selected from natural or synthetic curcuminoid(s); in combination with a pharmaceutically acceptable excipient(s), effective in increasing the bioavailability of the active compounds is disclosed herein.


Title: A SUSTAINED RELEASE ORAL COMPOSITION OF AN ANTIPSYCHOTIC AGENT

Publication No: WO2010/109475
Pub. Date - Int. Class - Applicant: - 30.09.2010 - A61K 9/14 - GENEPHARM INDIA PRIVATE LIMITED
A sustained release oral composition of an antipsychotic agent comprising antipsychotic agent, ?-carrageenan and one or more pharmaceutically acceptable excipients; wherein the antipsychotic agent is 2-[2-(4-dibenzo {b,f}[1,4-thiazepin-11yl -1-piperazinyl)ethoxy ethanol] or its pharmaceutically acceptable salt.


Title: COMPOSITION FOR USE IN GENE THERAPY

Publication No: WO2010/109176
Pub. Date - Int. Class - Applicant: - 30.09.2010 - A61K 9/00 - NTNU TECHNOLOGY TRANSFER AS
A compositions useful in gene therapy and method of treatment to effect gene therapy is provided. In particular, a parenteral pharmaceutical gene therapy composition comprising a non-immunogenic net polyanionic oligosaccharide associated with a particulate complex of an anionic nucleic acid material and a cationic macromolecule, optionally together with at least one pharmaceutical carrier or excipient, is provided.


Title: ABUSE RESISTANT FORMULATION

Publication No: WO2010/100414
Pub. Date - Int. Class - Applicant: - 10.09.2010 - A61K 9/16 - OREXO AB
There is provided a sustained-release pharmaceutical composition comprising a solid, continuous network comprising an excipient with a high mechanical strength, which network also comprises pores, within which pores is interspersed a mixture of an active ingredient and a film-forming agent, characterised in that said pores are formed during the production of the composition. Compositions of the invention find particularly utility as abuse-resistant formulations comprising opioid analgesics that may be employed in the treatment of chronic pain.


Title: AN ORAL PHARMACEUTICAL COMPOSITION OF DUTASTERIDE

Publication No: WO2010/092596
Pub. Date - Int. Class - Applicant: - 19.08.2010 - A61K 9/107 - GENEPHARM INDIA PRIVATE LIMITED
An oral pharmaceutical composition of dutasteride or its pharmaceutically acceptable salt comprising admixture of a) dutasteride or its pharmaceutically acceptable salt; b) one or more surfactant (s) /co-surfactant(s); c) one or more oil (s); d) optionally antioxidant (s); and e) optionally excipient (s); wherein the composition upon dilution with aqueous medium forms microemulsion with atleast 95% particles having mean particle size below 200 nm.


Title: DUAL RELEASE PHARMACEUTICAL SUSPENSION

Publication No: WO2010/089767
Pub. Date - Int. Class - Applicant: - 12.08.2010 - A61K 9/10 - PANACEA BIOTEC LTD.
Orally deliverable dual-release pharmaceutical suspensions, having a first portion comprising an immediate release form of the active in the solution form or granules or suspended form in the vehicle/medium preferably in the solution form and a second portion comprising a sustained-release form of active in the form of microgranules/microparticles suspended in the immediate release fraction of the solulabilised active agent which comprise a core and at least one coat suitable for liquid dosage forms for the administration of the active ingredients, wherein the core comprises at least one active agent(s) or its pharmaceutically acceptable salts, derivatives, isomers, polymorphs, solvates, hydrates, analogues, enantiomers, tautomeric forms or...


Title: PHARMACEUTICAL COMPOSITIONS OF TRIMETAZIDINE

Publication No: WO2010/086868
Pub. Date - Int. Class - Applicant: - 05.08.2010 - A61K 9/28 - LUPIN LIMITED
A once daily sustained release pharmaceutical compositions of Trimetazidine or a pharmaceutically acceptable salt(s), polymorph(s), solvate(s), hydrate(s), enantiomer(s) thereof using dual retard release technique. These compositions comprise a core comprising trimetazidine or a pharmaceutically acceptable salt(s), polymorph(s), solvate(s), hydrate(s), enantiomer(s) thereof, one or more sustained release polymer(s) in a matrix and one ore more pharmaceutically acceptable excipient(s), wherein the core is further coated with a functional coating. The compositions of the invention have reduced fluctuations of peak- valley plasma concentration as compared to 35mg twice daily modified release formulation.


Title: NOVEL DERIVATIVE OF ERYTHROMYCIN FOR THE TREATMENT AND DIAGNOSIS OF PRION DISEASE

Publication No: WO2010/084201
Pub. Date - Int. Class - Applicant: - 29.07.2010 - G01N 33/68 - COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES
The present invention concerns a pharmaceutical composition comprising the (E)-9-[O-(methyl 2-O-benzyl-4,6-O-benzylidene-ß-D-allopyranosid-3-yl)oxime] erythromycin A of formula (I) or pharmaceutically acceptable salts thereof, and a pharmaceutically carrier, excipient or diluent; a method of prophylactically and/or therapeutically treating amylo?d neurodegenerative diseases by administering to a subject in need thereof an effective amount of said pharmaceutical composition; a method for testing at least one sample obtained from a mammal, for the presence or absence of an aberrant prion protein (PrPres) in order to diagnose a Prion infection within said mammal, said method using (E)-9-[0-(methyl 2-O-benzyl-4,6-O-benzylidene-ß-D-allopyrano...


Title: PHARMACEUTICAL COMPOSITION COMPRISING MELOGLIPTIN

Publication No: WO2010/079433
Pub. Date - Int. Class - Applicant: - 15.07.2010 - A61K 31/4196 - GLENMARK PHARMACEUTICALS, S.A.
The present invention relates to a pharmaceutical composition for oral administration that includes melogliptin and at least one pharmaceutically acceptable excipient.


Title: PHARMACEUTICAL DOSAGE FORMS AND METHODS OF MANUFACTURING SAME

Publication No: WO2010/078429
Pub. Date - Int. Class - Applicant: - 08.07.2010 - A61K 31/216 - IMPAX LABORATORIES, INC.
The invention provides solid dispersions of at least one insoluble active pharmaceutical ingredient, pharmaceutical dosage forms comprising the solid dispersions, and methods of manufacturing same. In an embodiment, a solid dispersion of the present invention includes a plurality of coated particles comprising inert particles with a coating, wherein the coating comprises an insoluble active pharmaceutical ingredient dispersed in a hydrophilic polymer, and wherein the inert particles comprise nonpareils; and a plurality of granules comprising an insoluble active pharmaceutical ingredient with at least one pharmaceutically acceptable excipient. In an embodiment, the insoluble active pharmaceutical ingredient in the coating and the insoluble a...


Title: ORAL DOSAGE FORMS OF BENDAMUSTINE

Publication No: WO2010/063493
Pub. Date - Int. Class - Applicant: - 10.06.2010 - A61K 9/48 - ASTELLAS DEUTSCHLAND GMBH
In the present invention there is provided an oral pharmaceutical composition, comprising bendamustine or a pharmaceutically acceptable, ester, salt or solvate thereof as an active ingredient, and a pharmaceutically acceptable excipient, which is a pharmaceutically acceptable non-ionic surfactant, selected from the group consisting of polyethoxylated castor oil or derivative thereof and a block copolymer of ethylene oxide and propylene oxide.


Title: SOLID DOSAGE FORMS OF BENDAMUSTINE

Publication No: WO2010/063476
Pub. Date - Int. Class - Applicant: - 10.06.2010 - A61K 9/20 - ASTELLAS DEUTSCHLAND GMBH
In the present invention there is provided a pharmaceutical composition in a solid dosage form suitable for oral administration, the composition comprising bendamustine or a pharmaceutically acceptable ester, salt or solvate thereof as an active ingredient, and at least one pharmaceutically acceptable excipient, which is a pharmaceutically acceptable saccharide selected from the group consisting of one or more of a monosaccharide, a disaccharide, an oligosaccharide, a cyclic oligosaccharide, a polysaccharide and a saccharide alcohol, wherein the ratio by weight of the active ingredient to the saccharide excipient(s) is in the range of 1 :1-5.


Title: PHARMACEUTICAL AEROSOL COMPOSITION

Publication No: WO2010/052466
Pub. Date - Int. Class - Applicant: - 14.05.2010 - A61K 31/46 - CIPLA LIMITED
A pharmaceutical aerosol composition comprising at least one hydrofluoroalkane propellant; at least one active agent complexed with an adjuvant; and, optionally, at least one pharmaceutically acceptable excipient.


Title: PHARMACEUTICAL COMPOSITIONS OF TASTE-MASKED LINEZOLID

Publication No: WO2010/046933
Pub. Date - Int. Class - Applicant: - 29.04.2010 - A61K 9/00 - RUBICON RESEARCH PRIVATE LIMITED
The present invention relates to a pharmaceutical composition of linezolid for oral administration, comprising taste-masked linezolid and at least one pharmaceutically acceptable excipient. The taste-masked linezolid comprises linezolid and at least one taste-masking agent. The invention further relates to methods for masking the objectionable taste of linezolid by using at least one taste-masking agent and its incorporation into such palatable formulations. The pharmaceutical compositions of taste-masked linezolid are suitable for oral administration as suspensions, powders for suspensions, dispersible tablets, orally disintegrating tablets, chewable tablets, effervescent tablets and the like.


Title: MODIFIED RELEASE RAMIPRIL COMPOSITIONS AND USES THEREOF

Publication No: WO2010/029571
Pub. Date - Int. Class - Applicant: - 18.03.2010 - A61K 9/22 - PANACEA BIOTEC LIMITED
The invention relates to a modified release pharmaceutical composition comprising ramipril or pharmaceutically acceptable salts thereof and pharmaceutically acceptable excipient(s) wherein pharmaceutical composition is bioequivalent to conventional immediate release formulation of ramipril administered twice daily. The invention further relates to a modified release pharmaceutical composition comprising: an immediate release component comprising ramipril or pharmaceutically acceptable salts thereof and a modified release component comprising ramipril or pharmaceutically acceptable salts thereof. The invention further relates to the process for the preparation of modified release pharmaceutical composition of ramipril.


Title: CONTROLLED RELEASE COMPOSITIONS OF ROPINIROLE

Publication No: WO2010/023693
Pub. Date - Int. Class - Applicant: - 04.03.2010 - A61K 9/20 - LUPIN LIMITED
An oral controlled release pharmaceutical composition comprising a therapeutically effective amount of active substance, ropinirole or a pharmaceutically acceptable salt(s) or enantiomer (s) or polymorph (s) or hydrate (s) thereof, one or more controlled release agent (s), optionally one or more pharmaceutically acceptable excipient(s) and an extended release coating, wherein the said composition provides controlled release of the active agent with reduced initial burst release.


Title: PHARMACEUTICAL COMPOSITION COMPRISING AN EXTRACT OF CALENDULA SUBSPECIES

Publication No: WO2010/022485
Pub. Date - Int. Class - Applicant: - 04.03.2010 - A61K 36/28 - PROVETS SIMŐES LABORATÓRIA LTDA.
The present invention provides pharmaceutical compositions that include vegetal extracts, at least one hemostatic agent, and at least one optional ingredient possessing cicatrizating, antiseptic and/or hemostatic action. Specifically, the composition of the present invention is of topical use and uses extract of Calendula officinalis, aluminum potassium sulphate (Alum Potassium), zinc oxide, in a suitable pharmaceutical vehicle. The composition of the present invention is presented preferentially in the form of ointment that can be used in human beings as in animals as such as canines, felines, bovines and/or equines.


Title: TOPICAL HYDROGEL COMPOSITION

Publication No: WO2010/022031
Pub. Date - Int. Class - Applicant: - 25.02.2010 - A61K 31/65 - NANO THERAPEUTICS, INC.
Compositions for topical application to the skin and/or a wound are disclosed. In some embodiments, the compositions include a suspension or dispersion of particles of at least one poorly soluble drug chelated or otherwise complexed with a metal salt. The compositions may further contain at least one stabilizer, at least one excipient, and at least one physiologically acceptable carrier. Methods for making such compositions, pharmaceutical formulations containing such compositions, and methods of treatment utilizing such compositions are also disclosed.


Title: PHARMACEUTICAL FORMULATIONS OF AN HCV PROTEASE INHIBITOR IN A SOLID MOLECULAR DISPERSION

Publication No: WO2010/017432
Pub. Date - Int. Class - Applicant: - 11.02.2010 - A61K 9/20 - SCHERING CORPORATION
The present invention provides pharmaceutical formulations of an HCV protease inhibitor in a solid dispersion with an excipient which provided advantageous pharmacokinetic properties for inhibiting or treating HCV infection. In preferred embodiments, the excipient is at least one polymer. The present invention also provides processes for manufacturing such formulations as well as uses of said composition for the manufacture of a medicament for treating or ameliorating one or more symptoms of HCV or disorders associated with HCV in a subject in need thereof using said formulations.


Title: PARENTERAL COMPOSITION COMPRISING MICROSPHERES WITH A DIAMETER BETWEEN 10 AND 20 MICRONS

Publication No: WO2010/015665
Pub. Date - Int. Class - Applicant: - 11.02.2010 - A61K 9/16 - CORETHERAPIX SLU
The present invention relates to pharmaceutical formulations suitable for targeting particular tissue and/or organ(s) with a formulated active ingredient, for example when administered upstream of the target organ or tissue, and to use of the same in treatment, methods of treatment administering the same and methods of preparing the formulations. The pharmaceutical formulations of the invention are for parenteral administration to a target tissue and comprise particles containing an active ingredient, and a biodegradable excipient, wherein 90% or more of the particles have a diameter of between 10 and 20 microns and the formulation is substantially free of particles with a diameter greater than 50 microns and less than 5 microns, such that ...


Title: COMPOSITIONS AND METHODS FOR TREATMENT OF HYPERCHOLESTEROLEMIA

Publication No: WO2010/014541
Pub. Date - Int. Class - Applicant: - 04.02.2010 - A61K 9/16 - ALNARA PHARMACEUTICALS, INC.
The invention relates to compositions and methods for the treatment of patients with hypercholesterolemia. Embodiments of the invention include a pharmaceutical composition formulated for oral administration to a patient, wherein the pharmaceutical composition includes an effective amount of cholesterol oxidase, optionally at least one second therapeutic agent or cholesterol-lowering agent, and a pharmaceutically acceptable excipient for oral administration.


Title: PHARMACEUTICAL COMPOSITION

Publication No: WO2010/013823
Pub. Date - Int. Class - Applicant: - 04.02.2010 - A61K 9/14 - TAKEDA PHARMACEUTICAL COMPANY LIMITED
The present invention provides a pharmaceutical composition or a solid preparation containing a stabilized pharmaceutically active ingredient and a stabilizing method thereof. According to the present invention, a pharmaceutical composition can be stabilized by containing a nonpeptidic pharmaceutically active ingredient having a primary or secondary amino group, an excipient and an acidic compound. In addition, a solid preparation containing a pharmaceutically active ingredient, titanium oxide, a plasticizer and a chain organic acid can enhance the stability of the pharmaceutically active ingredient during light irradiation.


Title: ORAL COMPOSITIONS OF CLINDAMYCIN

Publication No: WO2010/010568
Pub. Date - Int. Class - Applicant: - 28.01.2010 - A61K 9/00 - LUPIN LIMITED
A taste masked pharmaceutical composition of clindamycin, or a pharmaceutically acceptable salt(s), hydrate(s), solvate(s) and physiologically functional derivative(s) and precursors thereof, which includes all polymorphic forms, whether crystalline or amorphous comprising polyhydric alcohol(s); and one or more other pharmaceutically acceptable excipient(s). A process for preparation of a taste masked pharmaceutical composition of clindamycin or a pharmaceutically acceptable salt(s) thereof the said process comprising the steps of a) dry mixing clindamycin, polyhydric alcohol and other pharmaceutically acceptable excipient(s) to get a dry mixture; b) granulating the dry mixture above with a granulating liquid prepared by mixing the suitable...


Title: TREATING INFLAMMATION AND RELATED CONDITIONS WITH IRINDALONE

Publication No: WO2010/006231
Pub. Date - Int. Class - Applicant: - 14.01.2010 - A61K 31/496 - ORE PHARMACEUTICALS INC.
A method for treating an inflammatory condition or immune disorder comprises administering to a subject having such a condition or disorder a therapeutically effective amount of at least one compound selected from irindalone, physiologically active enantiomers thereof, and pharmaceutically acceptable salts thereof. The invention further provides a method for elevating levels of anti-inflammatory cytokines such as IL- 10 and IL- 13 while inhibiting expression of pro-inflammatory cytokines. A pharmaceutical composition, useful for example in topical treatment of psoriasis, comprises a therapeutically effective amount of at least one compound selected from irindalone, physiologically active enantiomers thereof, and pharmaceutically acceptable ...


Title: THIOSEMICARBAZONE COMPOUNDS AND USE THEREOF

Publication No: WO2010/000008
Pub. Date - Int. Class - Applicant: - 07.01.2010 - C07D 213/53 - RICHARDSON, Desi, Raymond
A method of treating a proliferative disease in a vertebrate, the method comprising administering to the vertebrate a therapeutically effective amount of at least one compound of formula (I) (I) wherein R1 is selected from H, C1-6 alkyl, C2-6 alkenyl and phenyl; R2 is selected from H, C1-6 alkyl, C2-6 alkenyl and phenyl; wherein R1 and R2 are the same or different, or a salt, hydrate, or iron complex thereof, or a pharmaceutical composition comprising said compound, salt, hydrate or iron complex and a pharmaceutically acceptable carrier, diluent or excipient..
World Patents in Excipients, Delivery and Release of Pharmaceutical
Compositions and Actives Published in 2010
World  Patents Published  in 2011
World  Patents Published  in 2009
...or use our Search Engine to
search for patent documents by
number.
Search for anything. Simply
type the words in the box..
WORLD PATENTS IN EXCIPIENTS, DELIVERY AND RELEASE OF PHARMACEUTICAL ACTIVES PUBLISHED IN 2010
This list includes patent documents published by the World Intellectual Property Organization (WIPO). The list was retrieved by searching the claims section of all patent applications. Salient
search terms included pharmaceutical formulations, excipients, strips, gums, cellulose, lozenge, tablets, capsules, suppositories; solid dosage, nasal inhalation; time, control or sustained
drug release; polysaccharides, polymeric excipients, hyaluronic acid, micro- and nano-spheres, carbomer, povidone, polyacrylates, polymerthacrylates; emulsions; enemas, vaginal, rectal,
nasal, ocular or buccal administration of medications, etc.
Clck to enlarge and view details